A prospective survey of the control of acute and delayed antineoplastic and radiation-induced nausea and vomiting was undertaken in children undergoing bone marrow transplantation (BMT) at The Hospital for Sick Children. Prior administration of antineoplastic agents or irradiation, presence of anticipatory nausea or vomiting prior to starting the conditioning regimen, antiemetic use within 24 h of conditioning, the prescribed antineoplastic and/or radiation ablative regimen, and prescribed antiemetic regimens were recorded. Emetic episodes, dietary intake, administration of conditioning agents and antiemetics, and adverse effects were monitored on each day of the conditioning regimen and for 96 h thereafter. Children older than 3 years of age assessed their nausea on each study day. Twenty-five children were followed for 258 patient days. Children did not vomit or retch on 73% and 43% of patient days, in the acute and delayed phases, respectively. Nausea data were evaluable for 21 children on 200 patient days. Nausea was absent on 55% and 26% of patient days in the acute and delayed phases, respectively. Five children never had an emetic episode during the entire study period. One child was completely free from nausea and vomiting throughout the study period. Antineoplastic and radiation-induced nausea and vomiting can be successfully prevented in the majority of children undergoing BMT. However, effective treatment strategies must be developed in the event of antiemetic failure and for effective prophylaxis in children who cannot tolerate dexamethasone.
Without antiemetic support, 60-100% of BMT patients will experience nausea and vomiting during their conditioning regimens. 1 Several factors contribute to the unique emetogenicity of BMT conditioning regimens. Ablative therapies are administered over several days, so patients may experience acute and delayed nausea and vomiting simultaneously. Indeed, the number of emetic episodes per day increases as adults advance through BMT conditioning protocols. [1] [2] [3] In addition, cancer patients undergoing BMT may have a history of emesis and/or nausea with previous treatments of irradiation or chemotherapy. This may increase the likelihood of experiencing nausea and vomiting during their BMT conditioning regimen. 4 Control of nausea and vomiting is an important part of BMT supportive therapy. Poor control can lead to fluid, nutritional and electrolyte imbalances and occasionally, serious morbidity. 5 Poorly controlled nausea and vomiting can disrupt therapy if children are unable to tolerate oral medications or if they vomit during TBI. In addition, nausea and vomiting increase the anxiety and discomfort of transplant patients and their families. Severity of nausea and loss of appetite were included among the most distressing symptoms in women with breast cancer undergoing BMT. 6 Vomiting and nausea have been consistently ranked among the top three most significant symptoms experienced by adult cancer patients. 7, 8 Nausea may be more problematic for adult cancer patients than vomiting. 9 The objective of this study was to describe the effectiveness of antiemetic prophylaxis in children receiving antineoplastic agents and/or TBI prior to undergoing BMT.
Materials and methods
This study was approved by the Scientific Review Board of the Division of Haematology/Oncology and by the Research Ethics Board at The Hospital for Sick Children (HSC). Informed consent for participation in the study was obtained from patients у16 years of age and from guardians of patients 15 years old or younger. Assent was also obtained from patients aged 7 to 15 years.
Children р18 years of age admitted for BMT between December 1999 and May 2000 were recruited. Patients were excluded if they or their parents or guardians could not communicate in English or if they or their parents or guardians could not be contacted for consent before starting the ablative protocol.
Initial data collected for each patient included age, gender, weight, body surface area, diagnosis, prior administration of antineoplastic agents or irradiation, presence of anticipatory nausea or vomiting prior to starting the conditioning regimen, antiemetic use within 24 h of conditioning, prescribed antineoplastic and/or radiation ablative regimen, and prescribed antiemetic regimens.
The children were monitored daily from the first dose of conditioning and for 96 h after the final ablative agent was administered. Acute nausea and vomiting were assessed from the time of the first dose of the conditioning regimen until 24 h after the last dose of the conditioning regimen. Delayed nausea and vomiting were assessed over the 72 h that followed the acute phase.
An emetic episode was defined as a single vomit or retch separated by the absence of both vomiting and retching for at least 1 min. Vomiting was defined as the expulsion of stomach contents through the mouth. Retching was defined as an involuntary effort to vomit that did not produce stomach contents. Complete emetic control was defined as no emetic episodes per 24 h. A major emetic response included one or two emetic episodes per 24-h period. Emetic failure was defined as more than two emetic episodes per 24 h.
The worst degree of nausea experienced by the patient on each study day was assessed at bedtime by the patient, and recorded by the patient, parent or guardian. Patients who were older than 7 years of age graded their nausea as none (1 = no nausea at all), mild (2 = some nausea but did not interfere with his/her usual activities), moderate (3 = interfered with his/her activities), or severe (4 = required patient to be bedridden). Children who were 3 to 7 years old used a six-faced scale to assess their nausea. Face 0 indicated no nausea and face 5 indicated the worst nausea imaginable. Nausea was not assessed in patients younger than 3 years of age. Each child's diet was assessed daily at bedtime by the child and their parent or guardian and reflected the best diet achieved for that day. Dietary intake was classified as regular diet (1), fluids and some solids (2), fluids only (3), or nothing by mouth (4). If a child had a gastric tube or received TPN, this was noted.
Children or parents/guardians recorded the number and times of emetic episodes, severity of nausea, and dietary intake on diary cards each day. If children or parents/guardians were unable or unavailable, nurses completed the diary card.
On each day of data collection, one of the investigators contacted the patient or guardian to remind them to record data and answer questions about study procedures. Adverse reactions that were attributed to the antiemetics were recorded each day. Patients, parents or guardians, and the patient's medical chart were consulted daily to specifically determine the presence of diarrhea, constipation, headache, dizziness, hiccups, restlessness and hyperglycemia. Each day, investigators also noted the conditioning agent administered, antiemetics given, and the time of antiemetic and antineoplastic or TBI administration.
At the time of this study, the HSC guidelines for antiem- The proportions of complete, major and failed emetic responses, median nausea severity, median dietary intake, and proportion of days on which TPN was administered were described for the acute and delayed phases. The worst emetic response of each patient during the acute and delayed phases was described. The peak and mean number of daily emetic episodes for each conditioning regimen were also described. Proportions were compared by means of a Fisher's exact test with a two-sided a priori level of significance of 5% (SPSS 10.1 for Windows).
Results
Twenty-nine patients were scheduled for BMT during the recruitment period. Twenty-six patients were enrolled in the study. Three children were not enrolled due to inability to communicate in English (one patient), and failure to obtain consent prior to the start of the conditioning regimen (two patients). A fourth patient was excluded from analysis because the diary card was lost. No patient received IT therapy immediately prior to admission. No patients were receiving TPN at the start of the study period. One child had a gastric tube in place prior to admission and throughout the study period.
Twenty-five children were followed for 258 patient days. The acute and delayed phases comprised 183 and 75 patient days, respectively. The characteristics of the patients enrolled in the study are provided in Table 1 .
Effectiveness
Eighty-eight percent of children (22/25) experienced complete emetic control on at least one study day. Twenty percent (5/25) of patients never vomited or retched during the entire study period. Twenty-eight percent of children (7/25) never vomited or retched more than twice in any 24-h period. Fifty-two per cent of children (13/25) experienced antiemetic failure on at least one study day. Response data are summarized in Table 2 .
Nausea data were evaluable for 21 children on 200 patient days. Nausea was rated on 162 patient days by a total of 16 children older than 7 years and on 38 patient days by 5 children aged 3 to 7 years. Four patients did not rate their nausea because they were younger than 3 years 
Atgam = antithymocyte globulin; TBI = total body irradiation. of age. For two patients older than 7 years, nausea ratings were missing for 5 of 19 study days. Nausea ratings were missing on 8 of 18 study days for two patients aged 3 to 7 years. The median nausea ratings were 1 (no nausea) in children Ͼ7 years old and 2 (moderate nausea) in children 3 to 7 years old during the acute and delayed phases. Nausea was absent on 55% (79/143) and 26% (15/57) patient days during the acute and delayed phases, respectively. Four children never experienced nausea during the acute phase, while three were completely free from nausea during the delayed phase.
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Two children experienced neither nausea nor vomiting during the acute phase. Three children were free from both nausea and vomiting during the delayed phase. One child was completely free from both nausea and vomiting throughout the study period.
Dietary data were missing on 2 of 8 study days for one patient. All but one patient received TPN on at least 1 study day. The median dietary scores were 1 (regular diet) and 2 (fluids and some solids) during the acute and delayed phases, respectively.
Nine of 12 patients who had a failed emetic response in the acute phase also had a failed emetic response in the delayed phase. Nine of 10 patients who failed in the delayed phase also had experienced a failed emetic response in the acute phase on at least one day. Of the seven patients who never vomited or retched during the acute phase, five never vomited or retched in the delayed phase.
Influence of conditioning regimen
The conditioning regimens administered to study patients are summarized in Table 1 . During the acute phase, the etoposide-carboplatin-cyclophosphamide regimen was associated with the highest proportion of patient days on which a failed emetic response was observed (40%). The cyclophosphamide/TBI regimen was the second most emetogenic regimen with 25% of patient days associated with a failed response. This trend continued into the delayed phase with the etoposide-carboplatin-cyclophosphamide and the cyclophosphamide/TBI regimens leading to failed emetic responses on 38% and 19% of patient days, respectively. The single patient who received etoposidecyclophosphamide-melphalan had a failed emetic response on 2 of 3 days within the delayed phase.
Influence of anticipatory nausea or vomiting
Three patients reported anticipatory nausea or vomiting in the 24 h prior to starting the conditioning regimen. None of these children received treatment of anticipatory nausea or vomiting. The emetic responses, nausea scores, and diet scores are presented in Table 3 for patients with or without anticipatory nausea or vomiting. No relationship was observed between the presence of anticipatory nausea and vomiting and either vomiting or nausea in the acute or delayed phases.
Influence of prior exposure to antineoplastic agents or TBI
Twenty-one patients were exposed to antineoplastic agents prior to admission for BMT. The results for these patients and those without prior exposure are shown in Table 4 . No relationship was observed between prior exposure to antineoplastic agents and either vomiting or nausea in the acute or delayed phases.
Adverse effects
The most common adverse effect attributed to antiemetic agents was hyperglycemia associated with dexamethasone administration (23 patients). Two patients experienced adverse behavioural symptoms that resolved when dexamethasone was discontinued. Dexamethasone was discontinued in another patient due to hypertension. Two patients experienced unacceptable drowsiness with lorazepam. Two patients had dystonic reactions: one secondary to chlorpromazine and another due to metoclopramide.
Discussion
The HSC antiemetic selection guidelines in place at the time of this study are consistent with international guidelines for prophylaxis of nausea and vomiting after administration of high doses of antineoplastic agents and radiation. [10] [11] [12] At HSC, ondansetron plus dexamethasone are recommended as the standard prophylaxis with the exception that on days where busulfan is given as a single agent, ondansetron alone is recommended since busulfan has a low emetogenic potential in children. 13, 14 Evaluations of antiemetic efficacy in children undergoing BMT are limited and have used highly variable designs, agents, dosing regimens and conditioning regimens. Complete emetic responses have been observed on 41 to 83% of study days, while up to 54% of children have been reported to have had complete emetic control throughout conditioning. [13] [14] [15] [16] [17] [18] [19] Of these reports, Hewitt et al 16 achieved the best outcomes. Ondansetron, in doses similar to those given in the present study, was given to children receiving cyclophosphamide and TBI conditioning. Dexamethasone was not given; nausea was not assessed. Complete emetic control was achieved on 83% of patient days and one third of children were free from vomiting for the entire study period. Despite administration of more highly emetogenic regimens to a more variable group of patients, our results approach those of Hewitt et al. Few studies have evaluated nausea in children undergoing BMT, perhaps due to the inherent difficulties in assessing a subjective symptom in this age group. [14] [15] [16] 18 Certainly evaluation of the effectiveness of antiemetic regi-mens in children is seriously hampered by the lack of a validated nausea assessment tool. It is recommended that adults serve as proxies for children only when the outcomes to be assessed are definitive and objective. 20 In keeping with this philosophy, children in this survey rated their own nausea, while adults recorded emetic episodes. The faces scale used here was adapted from a validated assessment of pain in children. 21 It has been used to assess nausea in previous HSC studies 14, 22, 23 and resembles the nausea scale used by Orchard et al 15 in children as young as 2 years old. Orchard et al 15 monitored nausea daily from the start of conditioning until the day of transplant. Children, especially those 5 to 9 years old, reported less severe nausea compared with adults. Children also experienced a higher number of emetic episodes after the day of transplant when antiemetics had been discontinued. Children in our survey reported nausea of a higher severity during the delayed phase compared with the acute phase. This is consistent with adult reports of increasingly severe nausea beyond the transplant day despite emetic control. However, it is difficult to interpret observations regarding nausea in children since it is possible that the tool used was inappropriate or inaccurate and that children are unable to assess nausea as a discrete symptom. Nevertheless, control of nausea is likely less than adequate, especially during the delayed phase.
Delayed emesis has not been well studied in adults undergoing BMT and has been virtually ignored in children. Several studies collected emetic response data during the delayed phase, but did not report these results separately. [13] [14] [15] [16] [17] [18] [19] We have observed delayed vomiting in 33% of children with cancer receiving antineoplastic agents known to be associated with delayed nausea and vomiting in adults (cyclophosphamide, carboplatin and cisplatin). 23 Delayed vomiting appears to be more common in children after BMT (57%). Reasons for this difference are unknown. Adult patients have reported increased emesis on the day of transplant. 6 Although there is no specific supportive evidence, some have suggested that DMSO, which may be added to the marrow/stem cell infusion as a preservative, is an emetogen and thus may be partly responsible for decreased emetic control and increased nausea observed during the delayed phase. 17 It is also possible that TBI-or antineoplastic-induced mucositis may lead to nausea and vomiting in the delayed phase, though it would not be expected to play a large role within 3 days of transplant. Supportive medications administered after transplant (eg cyclosporine, antibiotics, antivirals) may also contribute to nausea and vomiting during the delayed phase. Also, gastroparesis has been reported as a cause of nausea and vomiting as early as 8 days after BMT. 24 Few of our patients experienced anticipatory nausea or vomiting or had not received antineoplastic agents prior to transplant. The evaluation of a relationship between either the presence of anticipatory nausea and vomiting or prior exposure to antineoplastic agents prior to BMT and vomiting and nausea control was compromised by this imbalance. These relationships must be elucidated in a larger sample.
The relatively poor response of our patients during the delayed phase indicates that this is an area where emetic and nausea control needs to be improved. While it is true Bone Marrow Transplantation that improved control in the acute phase may lead to improved control during the delayed phase, 4 prophylaxis must also be specifically developed for the delayed phase. The efficacy of HT-3 antagonists in preventing delayed phase vomiting is controversial. Corticosteroids, although effective, carry with them significant risks of morbidity. Evaluation of agents such as domperidone, metopimazine or neurokinin-1 antagonists which do not rely on activity at the HT-3 receptor may improve emetic control during the delayed phase.
Major educational efforts must be implemented to heighten the awareness of the entire care team regarding the need for meticulous attention to nausea and vomiting control in children undergoing BMT. However, it must be acknowledged that evidence-based treatment strategies for children who are identified as having failed prophylaxis are lacking. Future research in this field should focus on treatment strategies for antiemetic failure, alternative preventive strategies for patients who cannot receive dexamethasone and strategies to reduce nausea, especially during the delayed phase.
